GlassScriptPhysician profile
Christopher Yih
NPI 1427580729
$24,231.22
in general payments reported to CMS, 2019-2025
20 companies · $704 in 2025
The $704 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $208 · 2023: $3,368 · 2024: $20K · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $15K · Food and Beverage: $5,796 · Travel and Lodging: $2,461 · Education: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $15,000.00 |
| Food and Beverage | $5,796.02 |
| Travel and Lodging | $2,460.59 |
| Education | $766.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $16,935.71 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Medtronic, INC. | $2,647.05 | 2023-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Inceptiv |
| Nevro Corp. | $1,365.82 | 2023-2024 | Omnia, Senza |
| Abbott Laboratories | $510.49 | 2024 | Proclaim, Eterna, Octrode |
| Vertos Medical, INC. | $510.16 | 2023-2024 | Mild Device Kit |
| Saluda Medical Americas, INC. | $347.88 | 2024 | Evoke |
| Merz Pharmaceuticals, LLC | $347.60 | 2022-2024 | Xeomin |
| Relievant Medsystems, INC. | $321.21 | 2023 | Intracept |
| Mml US, INC. | $307.88 | 2024 | Reactiv8 |
| Bioventus LLC | $211.18 | 2024-2025 | Stimrouter Implantable Kit, Xcell |
| Spr Therapeutics, INC | $201.98 | 2024 | Sprint Pns System |
| Si-Bone, INC. | $133.29 | 2025 | |
| Curonix LLC | $126.58 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Protega Pharmaceutials INC | $59.09 | 2025 | Roxybond |
| Stratus Medical, LLC | $50.94 | 2023 | Nimbus |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.97 | 2024-2025 | Evenity, Prolia |
| Biotronik Nro, INC. | $30.83 | 2024 | Prospera |
| Nalu Medical, INC. | $29.11 | 2025 | Nalu Neurostimulation System |
| Pfizer INC. | $25.34 | 2024 | |
| Ibsa Pharma INC. | $21.11 | 2024 | Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Yih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.